Anixa Biosciences, Inc. (ANIX)
2.90
0.00 (0.00%)
USD |
NASDAQ |
Oct 12, 10:16
Anixa Biosciences Free Cash Flow (Quarterly) : -1.77M for July 31, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2026 | -1.77M |
| April 30, 2026 | -1.741M |
| January 31, 2026 | -2.61M |
| October 31, 2025 | -1.255M |
| July 31, 2025 | -1.511M |
| April 30, 2025 | -1.503M |
| January 31, 2025 | -2.904M |
| October 31, 2024 | -0.927M |
| July 31, 2024 | -2.643M |
| April 30, 2024 | -1.456M |
| January 31, 2024 | -2.309M |
| October 31, 2023 | -1.969M |
| July 31, 2023 | -1.445M |
| April 30, 2023 | -0.807M |
| January 31, 2023 | -1.988M |
| October 31, 2022 | -1.593M |
| July 31, 2022 | -1.396M |
| April 30, 2022 | -2.306M |
| January 31, 2022 | -1.197M |
| October 31, 2021 | -1.044M |
| July 31, 2021 | -1.481M |
| April 30, 2021 | -1.242M |
| January 31, 2021 | -1.170M |
| October 31, 2020 | -1.414M |
| July 31, 2020 | -1.291M |
| Date | Value |
|---|---|
| April 30, 2020 | -1.556M |
| January 31, 2020 | -1.930M |
| October 31, 2019 | -1.337M |
| July 31, 2019 | -0.6401M |
| April 30, 2019 | -1.610M |
| January 31, 2019 | -1.330M |
| October 31, 2018 | -1.028M |
| July 31, 2018 | -1.19M |
| April 30, 2018 | -0.7518M |
| January 31, 2018 | -1.342M |
| October 31, 2017 | -0.7526M |
| July 31, 2017 | -1.254M |
| April 30, 2017 | -1.076M |
| January 31, 2017 | -0.744M |
| October 31, 2016 | -0.6849M |
| July 31, 2016 | -0.8182M |
| April 30, 2016 | -1.387M |
| January 31, 2016 | -0.6384M |
| October 31, 2015 | -0.8019M |
| July 31, 2015 | -0.7085M |
| April 30, 2015 | -1.779M |
| January 31, 2015 | 4.598M |
| October 31, 2014 | -0.3621M |
| July 31, 2014 | -0.3373M |
| April 30, 2014 | -0.5078M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -181.32M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.30M |
| Sarepta Therapeutics, Inc. | 196.52M |
| Mera Pharmaceuticals, Inc. | -- |